PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00072852
- Locations
- π³πΏ
Pfizer Investigational Site, Wellington, New Zealand
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-10-13
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00071006
- Locations
- πΊπΈ
Pfizer Investigational Site, Houston, Texas, United States
CPG 7909 Injection in Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT00070642
CPG 7909 Injection in Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 116
- Registration Number
- NCT00070629
- Locations
- πΊπΈ
VA New Jersey Health Care System, East Orange, New Jersey, United States
π¨π¦Ottawa Regional Cancer Center, Ottawa, Ontario, Canada
π©πͺStaedtisches Krankenhaus Martha-Maria, Halle-Dolau, Germany
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-09-16
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 118
- Registration Number
- NCT00068952
- Locations
Pfizer Investigational Site
A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Phase 4
Completed
- Conditions
- First Posted Date
- 2003-09-08
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT00068042
- Locations
- π¬π§
Pfizer Investigational Site, London, United Kingdom
Pegvisomant And Sandostatin LAR Combination Study
Phase 4
Completed
- Conditions
- First Posted Date
- 2003-09-05
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT00068029
- Locations
- π¬π§
Pfizer Investigational Site, Oxford, United Kingdom
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-08-18
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT00067314
- Locations
- π«π·
Pfizer Investigational Site, Vandoeuvre Les Nancy, France
Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-08-05
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00026273
- Locations
- π«π·
Hopital Tenon, Paris, France
π¦πΉAllgemeines Krankenhaus der Stadt Wien, Vienna (Wien), Austria
π©πͺUniversitats-Krankenhaus Eppendorf, Hamburg, Germany
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2003-07-25
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00065468
- Locations
Pfizer Investigational Site
Β© Copyright 2024. All Rights Reserved by MedPath